Provided by Tiger Trade Technology Pte. Ltd.

Seres Therapeutics

5.10
-0.1800-3.41%
Volume:32.07K
Turnover:164.06K
Market Cap:51.23M
PE:-2.11
High:5.27
Open:5.24
Low:5.05
Close:5.28
52wk High:29.98
52wk Low:4.32
Shares:10.04M
Float Shares:8.83M
Volume Ratio:0.52
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4137
EPS(LYR):0.6400
ROE:-66.57%
ROA:-39.85%
PB:1.48
PE(LYR):7.97

Loading ...

Seres Therapeutics presents at H.C. Wainwright BioConnect investor conference

Reuters
·
May 12

Seres Therapeutics (MCRB) Gets a Buy from Canaccord Genuity

TIPRANKS
·
May 06

Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K

Benzinga Earnings
·
May 05

Seres Q1 FY26 net loss turns to USD 19.9 million; revenue at USD 358,000

Reuters
·
May 05

BRIEF-Seres Therapeutics Q1 EPS USD -2.08

Reuters
·
May 05

Seres Therapeutics Inc: as of March 31, 2026, Seres Had $29.8 Mln in Cash and Cash Equivalents,Expects to Fund Operations Through Q3 of 2026

THOMSON REUTERS
·
May 05

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

GlobeNewswire
·
May 04

Seres Therapeutics Inc expected to post a loss of $1.88 a share - Earnings Preview

Reuters
·
May 01

Seres Therapeutics announces three presentations at 2026 ESCMID congress

TIPRANKS
·
Apr 20

Seres says Phase 1b trial shows SER-155 shifts gut microbiome in allo-HCT patients

Reuters
·
Apr 20

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

GlobeNewswire
·
Apr 20

Seres Therapeutics presents at CARB-X Investor Day, highlights SER-428 development

Reuters
·
Apr 09

Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date

TIPRANKS
·
Mar 17

Seres Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 14

Canaccord Genuity Remains a Buy on Seres Therapeutics (MCRB)

TIPRANKS
·
Mar 13